Infantile Stage M Neuroblastoma With 11q Deletion, Mimicking Stage MS

A 4-month-old boy with abdominal distension was diagnosed with adrenal neuroblastoma with numerous metastases to the liver and nodules in the skin and muscles. Marked hepatomegaly spontaneously regressed with decreasing tumor marker levels, and the final diagnosis was stage M based on radiologic findings confirming metastasis to the pancreas. The neuroblastoma did not have the MYCN amplification but had an 11q aberration. Chemotherapy was initiated at age 6 months with a successful response. Our case reflects the heterogenous clinical behavior of neuroblastoma and highlights the challenging issue of the difference between stage M and stage MS neuroblastoma in infants.

[1]  A. M. Caroleo,et al.  A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease. , 2020, Journal of pediatric hematology/oncology.

[2]  A. Naranjo,et al.  Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Verri,et al.  Genome instability model of metastatic neuroblastoma tumorigenesis by a dictionary learning algorithm , 2015, BMC Medical Genomics.

[4]  O. Delattre,et al.  Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study) , 2011, British Journal of Cancer.

[5]  Gudrun Schleiermacher,et al.  Accumulation of segmental alterations determines progression in neuroblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Ruth Ladenstein,et al.  Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Ruth Ladenstein,et al.  Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Barbara Hero,et al.  The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Giovanni Cecchetto,et al.  The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Audrey Kauffmann,et al.  MYCN‐non‐amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4S , 2008, Molecular oncology.

[11]  S. Yoo,et al.  Pancreatic Metastasis in a Child Suffering with Treated Stage 4 Neuroblastoma , 2008, Korean journal of radiology.

[12]  F. Berthold,et al.  Loss in Chromosome 11q Identifies Tumors with Increased Risk for Metastatic Relapses in Localized and 4S Neuroblastoma , 2006, Clinical Cancer Research.

[13]  P. Babyn,et al.  Neuroblastoma with atypical metastases to cardiac and skeletal muscles: MRI features , 2003, Pediatric Radiology.

[14]  F. Berthold,et al.  Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis? , 2000, Medical and pediatric oncology.